The telemedicine service Doctis will buy out a controlling stake (51%) of the contract research company IPHARMA. The deal is expected to be closed by the end of 2021, its terms has not been disclosed.

The combined team will create a digital clinical research platform that will be part of the Doctis ecosystem. The service will provide an opportunity to organize communication between a patient and a doctor remotely. At the same time, the processing of the obtained data, their layout, comparison of research results will be carried out using artificial intelligence.

Product cards

Doctis, IPHARMA

Original (in Russian)